Morinaga Milk's B. longum BB536 Probiotic May Prevent Intestinal Disorders Induced by Animal-Based Diet
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading dairy product company in Japan, today unveiled new research showing that daily consumption of yogurt fortified with the company’s proprietary probiotic Bifidobacterium longum BB536 prevents the intestinal bacterial imbalance induced by an animal-based diet. BB536 maintained healthy levels of beneficial bacteria, while preventing increases of harmful levels of bacteria such as Bilophila.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160211005072/en/
Recently, studies have demonstrated the importance of maintaining balanced intestinal flora to overall health. However, the modern, fast-paced lifestyle — with its lack of sleep and exercise, irregular dietary habits and continual stress — threatens bacterial balance. Eating an animal-based diet in particular has been shown to cause an increase in harmful bacteria, a condition known as dysbiosis. This problem is not confined to the United States. Due to Westernization, animal-based diets are growing in popularity in countries across the world.
The effect of animal products on bacterial balance is strong and immediate. In fact, a 2014 study published in the scientific journal Nature showed that consumption of an animal-based diet composed entirely of meat and eggs for just one day caused negative changes in the composition and function of intestinal flora, including dysbiosis.1 However, consumption of BB536-fortified yogurt prevented these harmful changes, as shown in Morinaga’s new research.
“Consumption of BB536-fortified yogurt prevented the GI deterioration caused by an animal-based diet, which indicates it may be able to prevent various intestinal disorders caused by eating a poor diet — just by adding one BB536 yogurt to the daily diet per day,” Dr. Jin-zhong Xiao, General Manager of Morinaga’s Next Generation Science Institute, explained.
“Importantly, probiotics are not interchangeable.” Dr. Xiao points out that “Probiotics are all strain-specific, as each strain has different indications and characteristics. Bifidobacterium longum is one of the predominant bacteria in the human intestine, and it is clinically confirmed that yogurt containing BB536 is more efficacious for eliminating harmful substances and modulating intestinal microflora compared to conventional yogurt.”
In the study, 31 healthy adults were randomly classified into 3 groups (A, B and C). After an observation period of 7 days, the subjects consumed an animal-based diet consisting entirely of meat and eggs for 5 days (the animal-based diet period) followed by a balanced diet (the recovery period) for 14 days. Group A consumed no BB536 yogurt during the whole study period, while group B consumed 100g of BB536 yogurt twice a day during the recovery period only, and group C consumed 100g of BB536 yogurt twice a day during both the animal-based diet period and the recovery period. Throughout the study, fecal samples were collected, and intestinal bacterial flora was analyzed before and after the animal-based diet period and after the recovery period (Fig. 1).
BB536 Yogurt Prevents Decrease in Beneficial Bifidobacteria (Fig.2 Left)
Bifidobacteria counts in the feces decreased significantly during the animal-based diet period in both groups A and B. However, this decrease was not observed in subjects in group C, who consumed BB536 yogurt together with the animal-based diet. Moreover, the Bifidobacteria tended to decrease further during the recovery period in group A, which ate no BB536 yogurt, while it tended to increase in group B, getting close to the original condition before starting the animal-based diet. These findings demonstrate the potential of Bifidobacterium longum BB536 not only to prevent diet-related gut flora disorders, but also to aid in their recovery.
BB536 Yogurt Also Prevents Increase in Harmful Bilophila (Fig.2 Right)
Consistent with the results of the above-mentioned Nature study, the present study found that an animal-based diet increased a genus of harmful bacteria called Bilophila. Bilophila is thought to induce inflammation in the intestines by producing the harmful substance hydrogen sulfide, which damages the intestinal mucous membrane2 and has been reported to be elevated in patients with appendicitis.3 However, no significant increase of this harmful bacterial genus was observed in group C subjects. B. longum BB536 showed superior results in regulating intestinal function, had a protective effect against the enteropathogenic Escherichia coli O-1574 and helped eradicate the enterotoxigenic Bacteroides fragilis (ETBF), which is associated with the development of colorectal cancer.5
About Bifidobacterium longum BB536
BB536 is one of the strains of Human Residential Bifidobacteria, which naturally reside in human intestines and are natural parts of human digestive systems. It is one of the most thoroughly researched probiotic strains in the world. Morinaga has conducted research and development on BB536 for over 40 years and achieved GRAS status in the U.S. in 2009. Supported by over 120 published studies, BB536’s beneficial effects have been confirmed in such clinical areas as intestinal health, immunity, infection, and allergy.
Morinaga Milk Industry Co., Ltd. is one of the major dairy product companies in Japan. Founded in 1917 and employing over 3,000 people, Morinaga excels in innovative technology and offers dairy products and other beneficial functional ingredients to customers around the world. For more information, visit us at http://www.morinagamilk.co.jp/english/.
1. Nature 505, 559-563(2014)
2. Nature 487, 104-108(2012)
3. PLoS One 4, e95414(2014)
4. Bios. Microflora 22, 85-91(2003)
5. Anaerobe 18, 14-18(2012)
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom